SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity.


Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
31 08 2021
Historique:
pubmed: 25 8 2021
medline: 15 9 2021
entrez: 24 8 2021
Statut: ppublish

Résumé

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) possesses a discriminative polybasic cleavage motif in its spike protein that is recognized by the host furin protease. Proteolytic cleavage activates the spike protein, thereby affecting both the cellular entry pathway and cell tropism of SARS-CoV-2. Here, we investigated the impact of the furin cleavage site on viral growth and pathogenesis using a hamster animal model infected with SARS-CoV-2 variants bearing mutations at the furin cleavage site (S gene mutants). In the airway tissues of hamsters, the S gene mutants exhibited low growth properties. In contrast to parental pathogenic SARS-CoV-2, hamsters infected with the S gene mutants showed no body weight loss and only a mild inflammatory response, thereby indicating the attenuated variant nature of S gene mutants. This transient infection was sufficient for inducing protective neutralizing antibodies that cross-react with different SARS-CoV-2 lineages. Consequently, hamsters inoculated with S gene mutants showed resistance to subsequent infection with both the parental strain and the currently emerging SARS-CoV-2 variants belonging to lineages B.1.1.7 and P.1. Taken together, our findings revealed that the loss of the furin cleavage site causes attenuation in the airway tissues of hamsters and highlighted the potential benefits of S gene mutants as potential immunogens.

Identifiants

pubmed: 34425707
doi: 10.1128/mBio.01415-21
pmc: PMC8406294
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Spike Glycoprotein, Coronavirus 0
Vaccines, Attenuated 0
spike protein, SARS-CoV-2 0
Furin EC 3.4.21.75

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0141521

Subventions

Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP21wm0125008
Organisme : Ministry of Education, Culture, Sports, Science and Technology (MEXT)
ID : 16H06429
Organisme : MEXT | Japan Science and Technology Agency (JST)
ID : JPMJMS2025
Organisme : The Atlantic Philanthropies Director Gift Fund

Références

Nat Med. 2021 Mar;27(3):546-559
pubmed: 33654293
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
N Engl J Med. 2021 May 13;384(19):1866-1868
pubmed: 33761203
Nat Microbiol. 2021 Jul;6(7):899-909
pubmed: 33907312
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
Cell. 2020 Jul 9;182(1):50-58.e8
pubmed: 32516571
Front Public Health. 2015 Nov 26;3:269
pubmed: 26636066
J Gen Virol. 2020 Nov;101(11):1156-1169
pubmed: 32821033
PLoS Pathog. 2021 Jan 21;17(1):e1009233
pubmed: 33476327
Annu Rev Pharmacol Toxicol. 2021 Feb 19;:
pubmed: 33606962
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Nat Commun. 2021 Feb 8;12(1):866
pubmed: 33558541
Cytokine Growth Factor Rev. 2020 Jun;53:13-24
pubmed: 32475759
Elife. 2021 Jan 04;10:
pubmed: 33393462
Genome Med. 2020 Jul 28;12(1):68
pubmed: 32723359
Mol Cell. 2020 May 21;78(4):779-784.e5
pubmed: 32362314
J Virol. 2021 Apr 12;95(9):
pubmed: 33563656
J Immunol Methods. 2011 May 31;368(1-2):24-35
pubmed: 21334343
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Cell. 2021 Apr 29;184(9):2362-2371.e9
pubmed: 33735608
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Nat Commun. 2021 Feb 11;12(1):961
pubmed: 33574281
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Clin Infect Dis. 2021 Jul 15;73(2):e437-e444
pubmed: 32649739
Jpn J Infect Dis. 2020 Jul 22;73(4):304-307
pubmed: 32074516
Cytokine. 2005 Sep 21;31(6):454-8
pubmed: 16129617
Cell. 2020 Aug 6;182(3):744-753.e4
pubmed: 32553273
Emerg Microbes Infect. 2020 Dec;9(1):2673-2684
pubmed: 33251966
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
Cell Rep Med. 2020 Jul 21;1(4):100059
pubmed: 32835306
J Gen Virol. 2020 Aug;101(8):791-797
pubmed: 32430094
J Gen Virol. 2020 Sep;101(9):925-940
pubmed: 32568027
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Emerg Microbes Infect. 2020 Dec;9(1):837-842
pubmed: 32301390
Nat Commun. 2020 Nov 27;11(1):6078
pubmed: 33247138
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Cell. 2021 Apr 29;184(9):2523
pubmed: 33930298
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33180746
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
Curr Opin Virol. 2021 Jun;48:73-81
pubmed: 33906125
Cell Host Microbe. 2021 Apr 14;29(4):551-563.e5
pubmed: 33657424
PLoS Biol. 2021 Mar 24;19(3):e3001006
pubmed: 33760807
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Cell Rep Med. 2020 Oct 20;1(7):100121
pubmed: 32984855
Science. 2020 Dec 18;370(6523):1464-1468
pubmed: 33184236
J Virol. 2020 Aug 17;94(17):
pubmed: 32571797

Auteurs

Michihito Sasaki (M)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.

Shinsuke Toba (S)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Shionogi & Co., Ltd., Osaka, Japan.

Yukari Itakura (Y)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.

Herman M Chambaro (HM)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.

Mai Kishimoto (M)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.

Koshiro Tabata (K)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.

Kittiya Intaruck (K)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.

Kentaro Uemura (K)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Shionogi & Co., Ltd., Osaka, Japan.
Laboratory of Biomolecular Science, Faculty of Pharmaceutical Science, Hokkaido Universitygrid.39158.36, Sapporo, Japan.

Takao Sanaki (T)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Shionogi & Co., Ltd., Osaka, Japan.

Akihiko Sato (A)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Shionogi & Co., Ltd., Osaka, Japan.

William W Hall (WW)

International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
National Virus Reference Laboratory, School of Medicine, University College of Dublin, Ireland.
Global Virus Network, Baltimore, Maryland, USA.

Yasuko Orba (Y)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.

Hirofumi Sawa (H)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Global Virus Network, Baltimore, Maryland, USA.
One Health Research Center, Hokkaido Universitygrid.39158.36, Sapporo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH